Singapore: Benitec Biopharma appointed Mr Kevin Buchi to its board of directors. Mr Buchi served as CEO of Cephalon, through its $6.8 billion acquisition by Teva Pharmaceutical Industries in October 2011.

After the acquisition Mr Buchi served as corporate vice president, global branded Products of Teva Pharmaceuticals. Mr Buchi joined Cephalon in 1991 and held various positions, including CEO, CFO and head of business development prior to being appointed CEO.

Mr Buchi currently serves on the board of directors of Stemline Therapeutics, Forward Pharma and Alexza Pharmaceuticals. Mr Buchi has served on the board of Lorus Therapeutics, Canada, Encysive Pharmaceuticals, Celator Pharmaceuticals, and Mesoblast, Australia. Mr Buchi has also served as a member of the life sciences advisory board at Safeguard Scientifics.